Orthocell entered into a research collaboration agreement with DePuy Synthes Products for its Ortho-ATI® stem cell treatment for tendon and ligament regeneration. A joint multi-center study is slated for 1Q17 in Australia.
The collaboration was facilitated by Johnson & Johnson Innovation.
Ortho-ATI Autologous Tenocyte Implantation is a non-surgical approach to treat chronic, treatment-resistant tendon injuries that have a significant negative effect on daily living activities.
In previous studies, Ortho-ATI has been shown to be a cost effective, durable, non-surgical solution for hard-to-treat tendon injuries. The product is available in Australia and New Zealand for patients who have failed conservative treatment options.
Orthocell entered into a research collaboration agreement with DePuy Synthes Products for its Ortho-ATI® stem cell treatment for tendon and ligament regeneration. A joint multi-center study is slated for 1Q17 in Australia.
The collaboration was facilitated by Johnson & Johnson Innovation.
Ortho-ATI Autologous Tenocyte...
Orthocell entered into a research collaboration agreement with DePuy Synthes Products for its Ortho-ATI® stem cell treatment for tendon and ligament regeneration. A joint multi-center study is slated for 1Q17 in Australia.
The collaboration was facilitated by Johnson & Johnson Innovation.
Ortho-ATI Autologous Tenocyte Implantation is a non-surgical approach to treat chronic, treatment-resistant tendon injuries that have a significant negative effect on daily living activities.
In previous studies, Ortho-ATI has been shown to be a cost effective, durable, non-surgical solution for hard-to-treat tendon injuries. The product is available in Australia and New Zealand for patients who have failed conservative treatment options.
Copy to clipboard 
